High Response Rates to CAR-T Seen in Mantle Cell Lymphoma
In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma.
Lymphoma News
LYMPHOMA ADVISOR
Lymphoma News
COVID-19 Pandemic Delaying Treatments of Hematologic Cancers
Some US medical centers have canceled treatments and all centers have altered their policies and procedures out of precaution related to the COVID-19 pandemic.
DLBCL-Type Richter Transformation Associated With Worse Prognosis vs DLBCL
The development of aggressive lymphoma, typically DLBCL, in patients initially diagnosed with CLL is the defining characteristic of Richter transformation.
Induction in Transplant-Eligible Mantle Cell Lymphoma With Rituximab and Cytarabine Added to Rituximab and Bendamustine
The researchers found that high rates of remission could be achieved with induction therapy using rituximab/bendamustine in addition to rituximab/cytarabine.
Brentuximab Vedotin With Bendamustine for Patients With Refractory or Multiple Relapsed Classic Hodgkin Lymphoma
A retrospective analysis found encouraging evidence for the use of BvB in treatment of RR-cHL.
Glyphosate Exposure and Relative Risks of Non-Hodgkin Lymphoma or Multiple Myeloma
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
Psoriasis Linked to Increased Risk for Developing Cancer
Increased risk particularly seen with keratinocyte cancer and lymphomas.
Study Calls for Unified Grading System for CAR-T Toxicities
A study found that grading systems for assessing toxicities from CAR-T therapy produced inconsistent scores, prompting a call for a more unified grading approach.
Clinical Response to Tisagenlecleucel Confers HRQoL Benefit in Lymphoma
Patients with relapsed/refractory diffuse large B-cell lymphoma who responded to tisagenlecleucel also had improved health-related quality of life outcomes.
No Change in Transplant Outcomes for DLBCL With Addition of Rituximab to Conditioning
Overall survival, progression-free survival, and nonrelapse mortality were found to be similar in patients receiving BEAM conditioning with or without rituximab.
Intensive Immunochemotherapy May Yield Positive Outcomes in Burkitt Lymphoma
Researchers assessed data from Australian population-based lymphoma registries to determine the efficacy of intensive immunochemotherapy for Burkitt lymphoma.
Best Practices for Diagnosing Breast Implant-Associated Anaplastic Large Cell Lymphoma
In 2016, the World Health Organization classified BIA-ALCL as a novel lymphoma.
Priority Review Granted to Tazemetostat for Follicular Lymphoma Indication
The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Tazverik® (tazemetostat; Epizyme) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received at least 2 prior lines of systemic therapy.
Comparing Cost-Effectiveness of First-Line Treatment Approaches for Hodgkin Lymphoma
Of 5 treatment regimens assessed, a PET-adapted de-escalation treatment approach was found to be the most cost-effective in 87% of cases modelled.
BEGEV Salvage Regimen Linked to High Complete Remission Rates
5-year results from that a study on BEGV have confirmed its benefits in classical Hodgkin lymphoma.
Prognostic Factors for Patients Undergoing Autologous Stem Cell Transplant for DLBCL
Researchers assessed potential differences in transplant outcomes in Japan before and after the era that introduced rituximab treatment.
Molecular Targets Identified for Rare Type of Breast Implant–Associated Lymphoma
The JAK-STAT pathway as well as epigenetics may play a role in the development of breast implant–associated anaplastic large-cell lymphoma.
Brentuximab Vedotin May Improve Survival in Stage III/IV Classical Hodgkin Lymphoma
Patients who received treatment with brentuximab vedotin experienced improved progression-free survival.
Current and Prospective Treatment Options for Waldenström Macroglobulinemia
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
Pixantrone or Gemcitabine and Rituximab for Relapsed, Aggressive B-Cell Non-Hodgkin Lymphoma
Patients receiving pixantrone plus rituximab and patients receiving gemcitabine plus rituximab experienced similar progression-free survival.
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
